Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab tirumotecan + cisplatin + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Kelun-Biotech
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sacituzumab tirumotecan + cisplatin + pembrolizumab is a combination regimen under investigation for the treatment of advanced cancers. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody-drug conjugate (ADC) that utilizes an anti-TROP2 monoclonal antibody conjugated via a novel linker to a belotecan-derived topoisomerase I inhibitor payload[1][5]. Cisplatin is a platinum-based chemotherapy agent that induces DNA crosslinking and apoptosis in tumor cells. Pembrolizumab is a monoclonal antibody against PD-1, acting as a checkpoint inhibitor to stimulate anti-tumor immune responses. This combination is investigated especially for non-small cell lung cancer (NSCLC) and other solid tumors, aiming to combine targeted cytotoxic, chemotherapeutic, and immunotherapeutic mechanisms.
- Other names
- sac-TMT + cisplatin + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on sacituzumab tirumotecan + cisplatin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab tirumotecan + cisplatin + pembrolizumab.